Beckman Coulter Announces the Launch of its New DxN VERIS Molecular Diagnostic System* in the United Arab Emirates

Beckman Coulter Announces the Launch of its New DxN VERIS Molecular Diagnostic System* in the United Arab Emirates
30 December 2016 -
  • Beckman Coulter Announces the Launch of its New DxN VERIS Molecular Diagnostic System* in the United Arab Emirates
    Beckman Coulter Announces the Launch of its New DxN VERIS Molecular Diagnostic System* in the United Arab Emirates Beckman Coulter Announces the Launch of its New DxN VERIS Molecular Diagnostic System* in the United Arab Emirates

United Arab Emirates- Beckman Coulter, among the world's leading clinical diagnostics companies, today revealed the launch of its DxN VERIS Molecular Diagnostic System in the United Arab Emirates. The platform is anticipated to establish a brand-new criterion in molecular diagnostics screening by revolutionizing operations automation and boosting laboratory outcomes.

The launch enables Beckman Coulter Diagnostics to bring its 80-year legacy of automation and innovation in the professional diagnostics laboratory to the molecular diagnostics arena, supporting the company's goal of moving health care onward.

The DxN VERIS Molecular Diagnostics System is a totally automated, sample-to-answer tool for the quantitative analysis of molecular targets. The unique functions of the system are developed to make certain that the research laboratory can run several varied markers, at any type of provided time, with minimal hand-operated treatment. The DxN VERIS incorporates example intro, nucleic acid extraction, reaction arrangement, real-time PCR amplification and detection and results interpretation in a single instrument. This integrated technique enables molecular diagnostics laboratories to supply quick and dependable examination outcomes, while improving operations and decreasing variety of consumables.

"The DxN VERIS system represents a standard change in molecular diagnostics," claimed Ganesh Ramaswamy, senior vice-president, consumer procedures for high-growth markets at Beckman Coulter. "It provides a streamlined, versatile and LEAN workflow that produces quickly, accurate results for physicians and their clients."

The growing food selection of assays for use on the DxN VERIS Molecular Diagnostics System consists of the following CE-marked products:.
· VERIS CMV Assay for the measurable decision of human Cytomegalovirus (CMV) in plasma.
· VERIS HBV Assay for the quantitative dimension of Hepatitis B Infection (HBV) in human plasma and lotion.
· VERIS HCV Assay for the measurable measurement of Liver disease C Virus (HCV) in human plasma.
· VERIS HIV-1 Assay for measurable discovery of Human Immunodeficiency Virus kind 1 (HIV-1) in plasma.

Beckman Coulter is dedicated to fulfilling the developing demands of the clinical community and aims to increase the DxN VERIS Molecular Diagnostics System menu, in addition to introduce new assays currently in advancement.

About Beckman Coulter.

Beckman Coulter Diagnostics develops medical analysis products that assist breakthrough and enhance the professional lab. Beckman Coulter's tools, systems and examinations assist simplify procedures to improve performance, lower costs and speed the shipment of outcomes. For 80 years, Beckman Coulter has actually been a global leader dedicated to giving remedies to labs of all sizes - providing a broad profile of chemistry, immunoassay, haematology, urinalysis, microbiology, automation, details systems and molecular diagnostics. Beckman Coulter is dedicated to progressing healthcare for every single individual and moving science, innovation and the lab ahead. For additional information, visit www.beckmancoulter.com.